

Antonella Ravaggi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9413159/antonella-ravaggi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

3,600
citations

34
h-index

55
g-index

122
ext. papers

4,073
ext. citations

5.6
avg, IF

4.21
L-index

#	Paper	IF	Citations
116	VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients.. <i>Frontiers in Oncology</i> , 2022 , 12, 818613	5.3	
115	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	11
114	Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial. <i>BMC Cancer</i> , 2021 , 21, 561	4.8	0
113	Gene Expression Profiling of Olfactory Neuroblastoma Helps Identify Prognostic Pathways and Define Potentially Therapeutic Targets. <i>Cancers</i> , 2021 , 13,	6.6	5
112	Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. <i>Frontiers in Immunology</i> , 2021 , 12, 690201	8.4	6
111	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
110	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. <i>Cancers</i> , 2021 , 13,	6.6	2
109	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. <i>Theranostics</i> , 2021 , 11, 2987-2999	12.1	17
108	Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 584022	5.3	3
107	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. <i>International Journal of Cancer</i> , 2020 , 147, 565-574	7.5	4
106	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020 , 10, 1287	5.3	5
105	FXYS5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. <i>British Journal of Cancer</i> , 2019 , 121, 584-592	8.7	15
104	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 22730-22736	11.5	26
103	Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. <i>Cells</i> , 2019 , 8,	7.9	3
102	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 619-624	11.5	28
101	Claudin3 is localized outside the tight junctions in human carcinomas. <i>Oncotarget</i> , 2018 , 9, 18446-18453	3.3	4
100	Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: a multicentric prospective study. <i>European Journal of Cancer Prevention</i> , 2017 , 26, 346-350	2	3

99	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 63	12.8	39
98	Polymerase I (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017 , 144, 146-152	4.9	38
97	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. <i>Cancer Letters</i> , 2017 , 388, 320-327	4.9	52
96	RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients. <i>Scientific Reports</i> , 2017 , 7, 10528	4.9	10
95	Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer. <i>Laryngoscope</i> , 2017 , 127, E408-E414	3.6	22
94	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. <i>BMC Cancer</i> , 2017 , 17, 366	4.8	10
93	Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017 , 117, 494-502	8.7	7
92	lncRNAs as Novel Indicators of Patients Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. <i>Clinical Cancer Research</i> , 2017 , 23, 2356-2366	12.9	47
91	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. <i>Annals of Oncology</i> , 2016 , 27, 1511-9	10.3	15
90	HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. <i>Gynecologic Oncology</i> , 2016 , 141, 303-311	4.9	69
89	Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 52-5	3.5	7
88	Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 2341-2348	5.6	32
87	Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 469, 61-9	5.1	18
86	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12238-12243	11.5	123
85	The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. <i>Oncology Letters</i> , 2016 , 12, 2493-2500	2.6	7
84	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. <i>Annals of Oncology</i> , 2015 , 26, 1363-71	10.3	28
83	Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy. <i>Proteomics</i> , 2015 , 15, 365-73	4.8	20
82	Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. <i>Oncotarget</i> , 2015 , 6, 34617-28	3.3	10

81	Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. <i>PLoS ONE</i> , 2014 , 9, e113781	3.7	14
80	Protein network mapping of glucose metabolism in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5550-5550	2.2	
79	Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. <i>Journal of Translational Medicine</i> , 2013 , 11, 162	8.5	4
78	Class III β -tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. <i>American Journal of Obstetrics and Gynecology</i> , 2013 , 209, 62.e1-9	6.4	21
77	Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 2916-21	11.5	221
76	MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. <i>Clinical Cancer Research</i> , 2013 , 19, 4114-23	12.9	50
75	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, 1815-24	5.9	27
74	Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. <i>British Journal of Cancer</i> , 2013 , 109, 462-71	8.7	23
73	A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. <i>Oncogene</i> , 2012 , 31, 4559-66	9.2	64
72	Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. <i>BMC Clinical Pathology</i> , 2012 , 12, 22	3	33
71	Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. <i>ISRN Obstetrics & Gynecology</i> , 2012 , 2012, 245756		22
70	Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 2189-98	5.9	62
69	HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. <i>Clinica Chimica Acta</i> , 2011 , 412, 1447-53	6.2	90
68	Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. <i>International Journal of Gynecological Cancer</i> , 2011 , 21, 1613-21	3.5	22
67	Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. <i>British Journal of Cancer</i> , 2011 , 104, 1418-25	8.7	116
66	Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2496-506	4	93
65	Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. <i>European Journal of Cancer</i> , 2010 , 46, 944-53	7.5	70
64	Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. <i>AAPS Journal</i> , 2010 , 12, 504-18	3.7	48

63	Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. <i>BMC Cancer</i> , 2009 , 9, 253	4.8	17
62	Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 201, 70.e1-9	6.4	16
61	Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1015-21	3.5	16
60	Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. <i>PLoS ONE</i> , 2009 , 4, e7670	3.7	31
59	Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. <i>British Journal of Cancer</i> , 2008 , 99, 768-73	8.7	34
58	Mammaglobin B expression in human endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 1090-6	3.5	25
57	Claudin-7 expression in human epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008 , 18, 1262-71	3.5	30
56	Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. <i>Journal of Virology</i> , 2008 , 82, 1968-79	6.6	104
55	Overexpression of mammaglobin B in epithelial ovarian carcinomas. <i>Gynecologic Oncology</i> , 2007 , 105, 578-85	4.9	26
54	Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. <i>American Journal of Obstetrics and Gynecology</i> , 2007 , 196, 245.e1-11	6.4	72
53	HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. <i>Gynecologic Oncology</i> , 2006 , 100, 469-78	4.9	72
52	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. <i>Gynecologic Oncology</i> , 2006 , 103, 405-16	4.9	90
51	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. <i>Archives of Virology</i> , 2006 , 151, 1899-916	2.6	16
50	Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. <i>British Journal of Cancer</i> , 2002 , 86, 151-7	8.7	27
49	Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. <i>Minerva Ginecologica</i> , 2002 , 54, 133-44	1.2	6
48	Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. <i>Gynecologic Oncology</i> , 2001 , 81, 424-32	4.9	27
47	Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001 , 108, 804-8	3.7	28
46	Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. <i>Gynecologic and Obstetric Investigation</i> , 2001 , 51, 254-61	2.5	63

45	Increased levels of interleukin-10 and transforming growth factor- β in the plasma and ascitic fluid of patients with advanced ovarian cancer. <i>British Journal of Obstetrics and Gynaecology</i> , 2001 , 108, 804-808		27
44	Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. <i>Clinical Cancer Research</i> , 2001 , 7, 804s-810s	12.9	22
43	Effects of concurrent cisplatin administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 48, 997-1006	4	72
42	In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2000 , 183, 601-9	6.4	39
41	Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. <i>Gynecologic and Obstetric Investigation</i> , 2000 , 49, 194-203	2.5	21
40	Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells. <i>Obstetrics and Gynecology</i> , 2000 , 96, 422-430	4.9	2
39	Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. <i>Journal of Interferon and Cytokine Research</i> , 2000 , 20, 21-30	3.5	50
38	Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. <i>Journal of Virology</i> , 2000 , 74, 4729-37	6.6	122
37	Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. <i>Obstetrics and Gynecology</i> , 2000 , 96, 422-30	4.9	50
36	Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7--pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. <i>European Journal of Gynaecological Oncology</i> , 2000 , 31, 17-23	1.6	13
35	Influence of maternal CD4 levels on the predictive value of virus load over mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1). Study Group for Vertical Transmission. <i>Journal of Medical Virology</i> , 1999 , 58, 59-62	19.7	4
34	Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro. <i>Immunobiology</i> , 1999 , 200, 187-204	3.4	43
33	Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. <i>Obstetrics and Gynecology</i> , 1999 , 94, 78-82	4.9	14
32	Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. <i>Obstetrics and Gynecology</i> , 1999 , 94, 78-82	4.9	7
31	Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. <i>Journal of Virology</i> , 1999 , 73, 5402-10	6.6	129
30	Effects of retinoic acid combined with irradiation on the expression of major histocompatibility complex molecules and adhesion/costimulation molecules ICAM-1 in human cervical cancer. <i>Gynecologic Oncology</i> , 1998 , 70, 195-201	4.9	14
29	Retinoic acid up-regulates the expression of major histocompatibility complex molecules and adhesion/costimulation molecules (specifically, intercellular adhesion molecule ICAM-1) in human cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1998 , 179, 1020-5	6.4	5
28	Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. <i>Cancer</i> , 1998 , 83, 2346-52	6.4	54

27	Effects of retinoic acid combined with interferon-gamma on the expression of major-histocompatibility-complex molecules and intercellular adhesion molecule-1 in human cervical cancer. <i>International Journal of Cancer</i> , 1998 , 75, 254-8	7.5	7
26	Genetic evolution of the hypervariable region 1 in hepatitis C virus carriers with normal aminotransferase activities. <i>Research in Virology</i> , 1998 , 149, 439-44		
25	The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. <i>International Journal of Radiation Biology</i> , 1998 , 73, 699-704	2.9	21
24	Effects of retinoic acid combined with interferon-gamma on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. <i>International Journal of Gynecological Cancer</i> , 1998 , 8, 158-163	3.5	2
23	Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection 1998 , 54, 12		1
22	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997 , 90, 1309-1314	2.2	39
21	Comparison of competitive and non-competitive reverse transcription-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. <i>Journal of Virological Methods</i> , 1997 , 65, 123-9	2.6	6
20	Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM-1(CD54) and LFA-3(CD58) in human ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1997 , 7, 273-278	3.5	1
19	Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. <i>Hepatology</i> , 1997 , 26, 792-797	11.2	60
18	Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. <i>Hepatology</i> , 1997 , 26, 1012-7	11.2	39
17	Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT levels. <i>Liver</i> , 1997 , 17, 133-8		17
16	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997 , 90, 1309-1314	2.2	8
15	Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. <i>Journal of Medical Virology</i> , 1996 , 50, 276-82	19.7	5
14	Hepatitis C virus genotypes in northern Italy: clinical and virological features. <i>Journal of Clinical Microbiology</i> , 1996 , 34, 2822-5	9.7	18
13	Long-term follow-up of and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. <i>Transfusion</i> , 1995 , 35, 108-11	2.9	14
12	Emergence of hepatitis B virus S gene mutant in a liver transplant recipient. <i>Journal of Medical Virology</i> , 1995 , 47, 410-5	19.7	36
11	Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 265-9	9.7	25
10	Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. <i>Journal of Hepatology</i> , 1994 , 20, 833-6	13.4	52

9	Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. <i>Journal of Hepatology</i> , 1994 , 21, 858-65	13.4	8
8	Diagnosis of viral hepatitis with a nonisotopic hybridization assay. <i>Nuclear Medicine and Biology</i> , 1994 , 21, 441-7	2.1	1
7	Clinical significance of serum hepatitis C virus (HCV) RNA as marker of HCV infection. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 3008-12	9.7	18
6	Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 2280-4	9.7	23
5	Direct PCR amplification of HCV RNA from human serum. <i>Genome Research</i> , 1992 , 1, 291-2	9.7	29
4	Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. <i>Hepatology</i> , 1992 , 15, 685-9	11.2	26
3	Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. <i>Hepatology</i> , 1992 , 16, 877-81	11.2	85
2	Rapid screening of recombinant plasmids with a non-radioisotopic hybridization assay. <i>BioTechniques</i> , 1992 , 13, 506-8	2.5	
1	Heterogeneity of the hepatitis C virus genome. <i>Journal of Infectious Diseases</i> , 1991 , 163, 1383-4	7	3